⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

September 27, 2016HematologyOpen Access

Advances in the pathophysiology of primary immune thrombocytopenia

View Full Paper

Ask AI

Bookmark

Share

Abstract

A better understanding of the immunomodulatory effects of each ITP therapy is needed to best manage the disease.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Perera et al. (2016) studied this question.

synapsesocial.com/papers/69d71cbe8a0e2c5879bef2a8 https://doi.org/10.1080/10245332.2016.1219497

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Cell‐mediated lysis of autologous platelets in chronic idiopathic thrombocytopenic purpuraOriginal Research · 2006 · 163 citations
2Platelet Toll-like receptor expression modulates lipopolysaccharide-induced thrombocytopenia and tumor necrosis factor-α production in vivoOriginal Research · 2005 · 489 citations
3Total Remission of Severe Immune Thrombocytopenia after Short Term Treatment with RomiplostimOriginal Research · 2011 · 14 citations
4International consensus report on the investigation and management of primary immune thrombocytopeniaHuman Clinical Trial · 2009 · 2,277 citations
5Fcγ receptor IIB gene polymorphism in adult Japanese patients with primary immune thrombocytopeniaOriginal Research · 2013 · 19 citations